

October 28, 2020  
Eisai Co., Ltd.

**INTERNATIONAL NONPROPRIETARY NAME FOR ANTI-AMYLOID BETA  
PROTOFIBRIL ANTIBODY BAN2401 DECIDED AS LECANEMAB**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the International Nonproprietary Name (INN) for the investigational anti-amyloid beta (A $\beta$ ) protofibril antibody BAN2401 was decided as lecanemab. For details, please refer to [the Recommended INN List No. 84](#) in WHO Drug Information Volume 34, No. 3.

For lecanemab, a global clinical Phase III study (Clarity AD) for early AD as well as a the clinical Phase III study AHEAD 3-45 for preclinical AD are underway. Lecanemab is being jointly developed by Eisai and Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States).

\*\*\*